Will the eTag be a diagnostic explicitly tied to Erbitux and EGFR drugs?
We’re 100-percent focused right now on what we’re doing in the EGFR pathway, and the four approved drugs there are Herceptin, Iressa, Tarceva, and Erbitux. So certainly, our product will be focused on that set of drugs. Whether it’s specific to particular drugs or a broader panel is still part of the commercial planning that’s ongoing. Our plan is to have a commercial product in the EGFR pathway. How would you roll that out into reference laboratories? We have our own reference lab here in South San Francisco, and for HIV, for example, we have a direct-sales organization [that] communicates with HIV physicians directly, and we plan to do the same in oncology. We may go through the reference lab, we partnered with them in HIV. We run all the tests here, but the large reference labs do get used for access purposes in certain markets. When do you expect this current collaboration to finish? The collaboration itself should be relatively short certainly a matter of months, not quarters. How
